Back to Search
Start Over
Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis.
- Source :
- Annals of Pharmacotherapy; Apr2024, Vol. 58 Issue 4, p416-427, 12p
- Publication Year :
- 2024
Details
- Language :
- English
- ISSN :
- 10600280
- Volume :
- 58
- Issue :
- 4
- Database :
- Supplemental Index
- Journal :
- Annals of Pharmacotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 176034987
- Full Text :
- https://doi.org/10.1177/10600280231153863